Cantor Fitzgerald Reaffirms "Overweight" Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "overweight" rating restated by stock analysts at Cantor Fitzgerald in a report released on Thursday,Benzinga reports. They presently have a $215.00 price objective on the stock. Cantor Fitzgerald's price target suggests a potential upside of 14.45% from the stock's current price.

A number of other research firms also recently issued reports on KRYS. HC Wainwright reissued a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday. Citigroup increased their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Finally, Chardan Capital increased their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of "Buy" and a consensus target price of $210.00.

Krystal Biotech Stock Performance

KRYS stock traded up $5.24 during midday trading on Thursday, reaching $187.86. The company's stock had a trading volume of 293,600 shares, compared to its average volume of 260,850. The stock has a fifty day simple moving average of $157.37 and a two-hundred day simple moving average of $175.23. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34. The firm has a market capitalization of $5.40 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter last year, the firm posted $0.30 earnings per share. The business's revenue was up 116.4% compared to the same quarter last year. As a group, analysts forecast that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech during the third quarter valued at about $40,000. Values First Advisors Inc. bought a new stake in Krystal Biotech during the third quarter valued at about $53,000. GF Fund Management CO. LTD. bought a new stake in Krystal Biotech during the fourth quarter valued at about $95,000. Huntington National Bank boosted its position in Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company's stock valued at $104,000 after purchasing an additional 283 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company's stock valued at $107,000 after purchasing an additional 412 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).